For years, obesity was treated as a lifestyle challenge, managed through diet, exercise, and personal discipline. That narrative is now shifting. The rise of GLP-1 agonists such as Ozempic has repositioned obesity as a chronic medical condition that requires sustained intervention.

As global demand accelerates, a key question emerges. Can India replicate its generics success in the rapidly expanding obesity drug market?

A Market at an Inflection Point

India’s anti-obesity drugs market, valued at approximately USD 80 million in 2024, is projected to reach around USD 190 million by 2033, growing at a CAGR of 9.9 percent. A primary driver is affordability. Monthly treatment costs are expected to decline from approximately USD 120-145 to nearly USD 35-50 as generics scale.

This pricing shift is critical in a country with over 100 million diabetes patients and approximately 135 million obese adults. The implication is clear. Demand is no longer constrained by awareness alone, but by access, and that barrier is rapidly declining.

From Episodic Treatment to Chronic Care

GLP-1 therapies represent a structural shift in treatment models.

• Continuous care paradigm: Therapies like semaglutide enable long-term weight management, similar to chronic conditions such as diabetes or hypertension
• Expanding patient pool: Increased awareness, lifestyle changes, and medical endorsement are driving adoption
• Global relevance: The model aligns with rising obesity rates worldwide, positioning scalable suppliers at a strategic advantage 

This transition significantly expands the addressable market, both in India and globally.

India’s Strategic Entry into GLP-1

With the semaglutide patent expiry in March 2026, Indian pharma companies have moved decisively.

• 10+ launches underway: Including players such as Sun Pharma, Dr. Reddy’s Laboratories, Zydus Lifesciences, Alkem Laboratories, Torrent Pharmaceuticals, Natco Pharma, Glenmark Pharmaceuticals, and USV Pvt Ltd
• Diverse product formats: Pens, tablets, and oral formulations, already exceeding 50 brands in development
• Backward integration: Investments in peptide synthesis and delivery systems such as auto-injectors to strengthen control and margins
• Policy support: PLI incentives accelerating domestic manufacturing and reducing reliance on imports

This reflects a coordinated push to capture a projected USD 1.4-3.0 billion opportunity by 2030.

Peptide Capabilities as a Core Advantage

GLP-1 drugs, while complex, align closely with India’s existing strengths.

• Reverse engineering expertise: Proven ability to replicate and stabilize complex molecules at scale
• Cost advantage: Estimated 70 to 90 percent reduction compared to originator drugs
• Manufacturing depth: Established capabilities across biologics and injectables

This is less about building new capabilities and more about extending existing strengths into a higher value segment.

Reframing Go-to-Market

Global innovators such as Eli Lilly have shaped early narratives around responsible usage. Campaigns for therapies like Mounjaro and Zepbound emphasize physician supervision and long-term adherence, positioning obesity as a medical condition rather than a cosmetic concern.

Indian companies are adopting a similar approach.

• Dual positioning across diabetes and obesity
• Physician-led awareness and prescription pathways
• Balanced messaging to reduce misuse and over-commercialization

This reflects a shift from traditional promotion to disease education and patient stewardship.

The Road Ahead

India’s positioning in the obesity drug market is underpinned by four structural advantages.

• Cost leadership: Enables mass access across price-sensitive markets
• Scale readiness: Rapid portfolio expansion across multiple players
• Innovation potential: Early movement beyond generics into differentiated therapies
• Regulatory agility: Strong export orientation and ability to address global supply gaps

The opportunity is substantial, but execution will determine outcomes. Success will depend on scaling peptide capabilities, building differentiated brands, and forming global partnerships.

India’s pharma sector is entering the obesity drug market as a scaled and experienced operator with proven global impact.

The question is no longer whether India can lead, but how quickly it can translate capability into sustained global leadership.